Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Releases Earnings Results

Calliditas Therapeutics AB (publ) (NASDAQ:CALTGet Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74), Yahoo Finance reports. Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 133.08%. The firm had revenue of $28.43 million during the quarter, compared to the consensus estimate of $35.78 million.

Calliditas Therapeutics AB (publ) Stock Down 1.5 %

Shares of CALT opened at $22.42 on Friday. Calliditas Therapeutics AB has a 52 week low of $15.25 and a 52 week high of $29.30. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89. The stock has a fifty day moving average of $20.60 and a 200-day moving average of $21.19.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright dropped their price target on Calliditas Therapeutics AB (publ) from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Friday.

Get Our Latest Analysis on CALT

About Calliditas Therapeutics AB (publ)

(Get Free Report)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.

See Also

Earnings History for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.